spacer
home > epc > summer 2002 > editor's letter
PUBLICATIONS
European Pharmaceutical Contractor

Editor's Letter

2001 was not a great year for drug development. In their latest survey, CMR International report some interesting trends. The bad news is that the launch of new molecular entities (NMEs) in 2001 was at its lowest level for 10 years - only 31. The number of products derived from biotechnology increased to 35 per cent of the total, revealing a bleak picture for traditional pharmaceutical companies with only a peripheral interest in biotech. Indeed, of the 31 products only six came from the top 10 pharma companies with two from Europe and four from the US.


What did not decrease in 2001 was the expenditure on R&D by the industry - pharma alone spent an estimated US$43.6 billion, up from US$41.8 billion (an increase of four per cent). Thus the cost of NMEs approaches US$1.0 billion, however you calculate the cost. The further piece of bad news is that the cost goes up while productivity apparently goes down.

With few exceptions the promise of genomics, high throughput screening and combinatorial chemistry have not yet delivered their undoubted potential and so pressure is mounting inexorably on so-called downstream activities such as clinical development, to increase their productivity, decrease costs and cut development times. As ever, I believe that outsourcing does offer major opportunities for both cost and time reduction.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Graham Hughes
spacer
Dr Graham Hughes
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Arcis Biotechnology appointments Professor Steve Howell as Non-Executive Chairman

Daresbury, UK, 24 July 2019: Arcis Biotechnology (“Arcis”), the nucleic acid sample preparation solution provider, today announced it has appointed Professor Steve Howell as Non-Executive Chairman of its Board of Directors. Steve takes over the position from Paul Foulger, who was serving as Chairman on an interim basis on behalf of the Board.
More info >>

White Papers

Achieve full compliance with tamper-verification pharma solutions

UPM Raflatac

UPM Raflatac has developed a range of pharmaceutical labelling products to support compliance with the Falsified Medicines Directive on packaging for prescription drugs and high-risk, over-the-counter medicines. Few solutions offer the same ease of adoption for meeting the February 2019 deadline.
More info >>

 
Industry Events

CPhI & P-MEC India

26-28 November 2019, India Expo Centre, Greater Noida, Delhi NCR, India

As the pharma industry looks increasingly towards India for high quality, low cost pharma solutions, CPhI & P-MEC India is the ideal event for companies wanting to pick up on the latest trends and innovations the market has to offer. At CPhI & P-MEC India, you will meet the movers and shakers from India's pharma machinery, technology and ingredients industries, giving you a competitive advantage that will help grow your business.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement